Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer

References

• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938–1948.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008 May 20;26(15):2568–2581.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019 Feb;9(2):176–198.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020 Dec;17(12):725–741.
   PubMed Web of Science ®Google Scholar
• Quinn KM. Innovative approaches to immunotherapy in breast cancer. J Thorac Dis. 2020 Aug;;12(8):4536–4540.
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013 Mar 1;31(7):860–867.
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sep 20;32(27):2959–2966.
   PubMed Web of Science ®Google Scholar
• Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019 Mar 1;37(7):559–569.
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Vingiani A, Maisonneuve P, et al. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. Breast Cancer Res Treat. 2020 Sep;183(2):347–354.
   PubMed Web of Science ®Google Scholar
• Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials—USOR 06–090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J clin oncol. 2017 Apr 11;35(23):2647–2655.
   PubMed Web of Science ®Google Scholar
• Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):497–509. doi: 10.1016/S1470-2045(18)30111-6.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747–756. doi: 10.1016/S1470-2045(14)70160-3.
   PubMed Web of Science ®Google Scholar
• Gupta S, Nair N, Hawaldar R, et al. Abstract GS5-01: addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: a phase III randomized controlled trial. Cancer Res. 2023 Jun;83:GS5–01.
   Google Scholar
• Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007 May;56(5):739–745.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018 Mar;18(3):153–167.
   PubMed Web of Science ®Google Scholar
• Verma V, Shrimali RK, Ahmad S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 Sep;20(9):1231–1243.
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019 Jan 15;18(1):10.
   PubMed Web of Science ®Google Scholar
• A V C, Brodie DW, Gilbert RJC, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002 Aug;17(2):201–210.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013 Apr;13(4):227–242.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014 Apr 1;32(10):1020–1030.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480–1492.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040–2051.
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924–937.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Drake CG, Sznol M, et al. Survival, Durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015 Jun 20;33(18):2013–2020.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang Z, Zheng X, et al. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol. 2021;11:562315.
   PubMedGoogle Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021 Aug;32(8):994–1004.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817–1828.
   PubMed Web of Science ®Google Scholar
• Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022 Jul 21;387(3):217–226.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020 Feb 27;382(9):810–821.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Denkert C, O’Shaughnessy J, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: exploratory analysis from KEYNOTE-522. J clin oncol. 2022 Jun 1;40(16_suppl):503.
   Google Scholar
• Shah M, Osgood CL, Amatya AK, et al. FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer. Clin Cancer Res. 2022 Dec 15;28(24):5249–5253.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine (U.S.). I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer. [Internet]. 2010 [cited2023 Jul]. https://www.clinicaltrials.gov/study/NCT01042379?cond=I-SPY2&rank=3
   Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized i-spy2 trial. JAMA Oncol. 2020 May 1;6(5):676–684.
   PubMed Web of Science ®Google Scholar
• Chien AJ, Soliman HH, Ewing CA, et al. Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: results from the I-SPY 2 trial. J clin oncol. 2021 May 20;39(15_suppl):508.
   Web of Science ®Google Scholar
• Fasching PA, Hein A, Kolberg HC, et al. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041). Eur J Cancer. 2023;May 184 1–9.
   PubMed Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug 1;30(8):1279–1288.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine (U.S.). Sharp & Dohme LLC M. Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer. [Internet]. 2018 [cited2023 Jul]. https://clinicaltrials.gov/study/NCT03639948?cond=NCT03639948&rank=1
   Google Scholar
• A V B, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67–76.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec 6;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 14;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 Oct 10;396(10257):1090–1100.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Loibl S, Jackisch C, Rastogi P, et al. GeparDouze/NSABP B-59: a randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. Ann Oncol. 2019 May 1;30:iii38.
   Web of Science ®Google Scholar
• Ademuyiwa FO, Gao F, Street CR, et al. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer. 2022;8(1):134.
   PubMed Web of Science ®Google Scholar
• Kern P, Kalisch A, Kolberg HC, et al. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response. Chemotherapy. 2013;59(5):387–394.
   PubMed Web of Science ®Google Scholar
• Ademuyiwa FO, Chen I, Luo J, et al. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Aug;189(1):187–202.
   PubMed Web of Science ®Google Scholar
• Sharma P, López-Tarruella S, García-Saenz JA, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018 Dec 1;24(23):5820–5829.
   PubMed Web of Science ®Google Scholar
• Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: neoTRIP Michelangelo randomized study. Ann Oncol. 2022 May;33(5):534–543.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine (U.S.). Pharma AG|Phaon Scientific GmbH|university hospital r, hospital erlangen E. study to compare a mono atezolizumab window followed by a atezolizumab - CTX therapy with atezolizumab-CTs therapy. [Internet]. 2021 [cited2023 Jul]. https://clinicaltrials.gov/study/NCT04770272?cond=NCT04770272&rank=1
   Google Scholar
• Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017 Sep 14;3(9):e172411.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage iii non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Devaux A, Beniuga G, Quaghebeur C, et al. Abstract P4-07-16: b-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers. Cancer Res. 2023 Mar 1;83(5_Supplement): P4-07-16-P4-07–16.
   Web of Science ®Google Scholar
• McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res. 2016 Dec 1;22(23):5729–5737.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine (U.S.). Sloan kettering cancer center m. peri-operative ipilimumab+nivolumab and cryoablation in women with triple-negative breast cancer. [Internet]. 2018 [cited2023 Jul]. https://clinicaltrials.gov/study/NCT03546686?cond=NCT03546686&rank=1
   Google Scholar
• National Library of Medicine (U.S.). Squibb BM. Pre-operative trial for breast cancer with nivolumab in combination with novel IO. [Internet]. 2019 [cited2023 Jul]. https://clinicaltrials.gov/study/NCT03815890?cond=BELLINI&rank=1
   Google Scholar
• National Library of Medicine (U.S.). Evaluate the clinical benefit of a post-operative treatment associating radiotherapy + nivolumab + ipilimumab versus radiotherapy + capecitabine for triple negative breast cancer patients with residual disease. [Internet]. 2019 [cited2023 Jul]. https://clinicaltrials.gov/study/NCT03818685?cond=NCT03818685&rank=1
   Google Scholar
• Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(3):e175–86. Mar.
   PubMed Web of Science ®Google Scholar
• Lassen U. Combining PARP inhibition with PD-1 inhibitors. Lancet Oncol. 2019 Sep;20(9):1196–1198.
   PubMed Web of Science ®Google Scholar
• Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP inhibitor efficacy depends on cd8+ t-cell recruitment via intratumoral sting pathway activation in brca-deficient models of triple-negative breast cancer. Cancer Discov. 2019 Jun;9(6):722–737.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP Inhibitor upregulates pd-l1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017 Jul 15;23(14):3711–3720.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020 Sep;21(9):1155–1164.
   PubMed Web of Science ®Google Scholar
• Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13–21.
   PubMed Web of Science ®Google Scholar
• Oualla K, El-Zawahry HM, Arun B, et al. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Vol. 9. Fes, Morocco: Therapeutic Advances in Medical Oncology; 2017.
   Google Scholar
• National Library of Medicine (U.S.). Testing MK-3475 (Pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer. [Internet]. 2016 [cited 2023 Jul]. https://clinicaltrials.gov/study/NCT02954874?cond=NCT02954874&rank=1
   Google Scholar
• Conte PF, Dieci MV, Bisagni G, et al. Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: the A-BRAVE trial. J clin oncol. 2020 May 20;38(15_suppl): TPS598–TPS598.
   Google Scholar
• National Library of Medicine (U.S.). Cancer institute (NCI) N. pembrolizumab vs. observation in people with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab. [Internet]. 2023 [cited 2023 Jul]. https://www.clinicaltrials.gov/study/NCT05812807?cond=NCT05812807&rank=1
   Google Scholar
• Sharma P. Time to optimize deescalation strategies in triple-negative breast cancer? Clin Cancer Res. 2022 Nov 14;28(22):4840–4842. doi: 10.1158/1078-0432.CCR-22-2140. Internet
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, McArthur HL, Bailey A, et al. ALEXANDRA/IMpassion030: a phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer. Ann Oncol. [Internet]. 2019[cited 2023 Jul];30:v97 https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02073596/full
   Web of Science ®Google Scholar
• Isaacs C, Nanda R, Chien J, et al. Abstract GS5-03: evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: results from the neoadjuvant I-SPY 2 TRIAL. Cancer Res. 2023 Mar 1;83(5_Supplement):GS5-03-GS5–03.
   Web of Science ®Google Scholar
• Yeung KT, Kalinsky K, Yau C, et al. Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: results from the neoadjuvant I-SPY 2 TRIAL. J clin oncol. 2023 Jun 7;41(17_suppl):LBA520–LBA520.
   Web of Science ®Google Scholar
• National Library of Medicine (U.S.). Squibb BM. Neoadjuvant nivolumab and chemotherapy in patients with localized triple-negative breast cancer. [Internet]. 2020 [cited2023 Jul]. https://clinicaltrials.gov/study/NCT04331067?cond=NCT04331067&rank=1
   Google Scholar
• National Library of Medicine (U.S.). The efficacy and safety of sintilimab plus anlotinib combined with chemotherapy as neoadjuvant therapy in TNBC. [Internet]. 2021 [cited2023 Jul]. https://clinicaltrials.gov/study/NCT04877821?cond=NCT04877821&rank=1
   Google Scholar
• Zhang L, Lin W, Tan F, et al. Sintilimab for the treatment of non-small cell lung cancer. Vol. 10. Beijing, China: Biomarker Research; 2022.
   Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11.
   Web of Science ®Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017 Jun;376(22):2147–2159.
   PubMed Web of Science ®Google Scholar
• Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26:12.
   Web of Science ®Google Scholar
• Page D, Pucilowska J, Bennetts L, et al. Abstract P2-09-03: updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count. Cancer Res. 2019;79(4_Supplement).
   Web of Science ®Google Scholar
• Shah AN, Flaum L, Helenowski I, et al. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8:1.
   Web of Science ®Google Scholar
• Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec;33(12):1250–1268.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:8.
   Web of Science ®Google Scholar